Chen Chen

Matthew Yan

Paul Choi

- HUTCHMED (China) Limited announced positive Phase III results from its **FRUSICA-2 registration clinical trial** for the fruquintinib and sintilimab combination in advanced renal cell carcinoma.  **[1648257_0001648257-25-000071_hcm-20251014xex99d1.htm:0]** 
- The combination demonstrated a median progression-free survival (PFS) of **22.2 months**, significantly higher than the **6.9 months** for axitinib/everolimus monotherapy (HR **0.373**; _p_ <**0.0001**).  **[1648257_0001648257-25-000071_hcm-20251014xex99d1.htm:0]** 
- The objective response rate (ORR) was **60.5%** for the combination, compared to **24.3%** for the control group (_p_ <**0.0001**), with a median duration of response (DoR) of **23.7 months** versus **11.3 months**.  **[1648257_0001648257-25-000071_hcm-20251014xex99d1.htm:0]** 
- A New Drug Application (NDA) for the fruquintinib and sintilimab combination has been **accepted for review by the China National Medical Products Administration (NMPA)**.  **[1648257_0001648257-25-000071_hcm-20251014xex99d1.htm:0]**

HUTCHMED (China) (HCM)